Loading clinical trials...
Loading clinical trials...
Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure
Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion. The ICG-clearance will be evaluated as a prognostic marker in liver disease.
patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
University of Heidelberg
Heidelberg, Germany
Start Date
October 1, 2005
Primary Completion Date
October 1, 2010
Completion Date
October 1, 2010
Last Updated
October 11, 2010
40
ESTIMATED participants
Indocyangreen (ICG) clearance
PROCEDURE
Lead Sponsor
Heidelberg University
NCT07329036
NCT06831643
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06169592